{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008918","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.756463+00:00","generated_at":"2026-06-01T06:14:52.932020+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Coherus BioSciences appoints Rita A. Karachun to Board of Directors","bullets":["Board size increased from 10 to 11; Karachun appointed as Class II director effective May 31, 2024.","To serve on Audit Committee; received option for 168,000 shares vesting over 3 years.","Previously SVP & Global Controller at Merck & Co. (2014-2023).","Annual cash retainer of $60k for board and audit committee service."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008918","json":"https://secwatch.observer/filing/0001558370-24-008918.json","markdown":"https://secwatch.observer/filing/0001558370-24-008918.md","text":"https://secwatch.observer/filing/0001558370-24-008918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024008918/0001558370-24-008918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024008918/chrs-20240531x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:14:52.932020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0492757e3","claim":"Rita A. Karachun was appointed as Class II Director at Coherus Oncology, Inc..","evidence_excerpt":"the vacancy on the Board created by such increase would be filled by the appointment of Rita A. Karachun, with such appointment becoming effective upon the receipt of certain confirmations, which were received May 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024008918/0001558370-24-008918-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}